Fundraising Fox
Biofrontera
NASDAQ: BFRIWoburn, US · Founded 2015 · Delaware corporation · 80 employees on LinkedIn
Find your way into Biofrontera
Sign up to see every warm intro you have to Biofrontera
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Biofrontera team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biofrontera develops treatments for actinic keratosis and other common skin conditions, aimed at improving outcomes for dermatology patients and providers. The company operates in the pharmaceutical and dermatology space.
Founders & leadership
Biofrontera was founded in 2015 by Hermann Luebbert.
EF
Eugene Frederick Leffler, IIIExecutive
FL
Fred LefflerChief Financial OfficerFred Leffler is Chief Financial Officer of Biofrontera, a pharmaceutical company developing treatments for actinic keratosis and other skin conditions. He has held senior financial leadership roles across healthcare, consumer products, manufacturing, and energy sectors, with experience in building teams at both large organizations and smaller companies with revenues exceeding $200 million, as well as in IPO and SPAC processes.
GJ
George JonesChief Commercial Officer (CCO)George Jones is Chief Commercial Officer at Biofrontera and brings 25 years of pharmaceutical industry experience, including prior roles as Vice President of Sales and Marketing at Pernix Therapeutics and Senior Director of Marketing at Depomed, where he oversaw product relaunches and portfolio optimization across dermatology and specialty care brands.
EF
Erica F GatesNamed on SEC filing
JJ
John J III BorerNamed on SEC filing
LM
Loretta M WedgeNamed on SEC filing
EL
Board
JJ
John J. Borer IIIBoard director
BH
HL
Heikki LanckrietBoard director
KD
Kevin D. WeberBoard director
Reported raises · per SEC filings
Form D private placements$58.4M disclosed across 7 rounds · 2021–2025
▶$11MraisedJul 2025 · 5 investors · PharmaceuticalsRule 506(b)
▶$11MraisedJul 2025 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Beth HoffmanDirector
- John J. Borer IIIDirector
- Hermann LuebbertExecutive Officer, Director
- Eugene Frederick Leffler, IIIExecutive Officer
- Heikki LanckrietDirector
- Kevin D. WeberDirector
- Offering amount
- $11M
- Amount sold
- $11M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedDec 2024 · 5 investors · PharmaceuticalsRule 506(b)
▶$4.2MraisedDec 2024 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John J. Borer IIIDirector
- Beth HoffmanDirector
- Hermann LuebbertExecutive Officer, Director
- Heikki LanckrietDirector
- Eugene Frederick Leffler, IIIExecutive Officer
- Kevin D. WeberDirector
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMar 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$8MraisedMar 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D. WeberDirector
- John J. Borer IIIDirector
- Eugene Frederick Leffler, IIIExecutive Officer
- Hermann LuebbertExecutive Officer, Director
- Beth HoffmanDirector
- Heikki LanckrietDirector
- Offering amount
- $8M
- Amount sold
- $8M
- Sales commissions
- $685K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.7MraisedNov 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$3.7MraisedNov 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John J III BorerDirector
- Kevin D WeberDirector
- Hermann LuebbertExecutive Officer, Director
- Erica F GatesExecutive Officer
- Erica L MonacoExecutive Officer
- Eugene Frederick LefflerExecutive Officer
- Loretta M WedgeDirector
- Beth J HoffmanDirector
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.1MraisedAug 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$7.1MraisedAug 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Erica L MonacoExecutive Officer
- Hermann LuebbertExecutive Officer, Director
- Beth J HoffmanDirector
- Kevin D WeberDirector
- John J III BorerDirector
- Loretta M WedgeDirector
- Erica F GatesExecutive Officer
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.4MraisedMay 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$9.4MraisedMay 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D WeberDirector
- Loretta M WedgeDirector
- Erica L MonacoExecutive Officer
- Beth J HoffmanDirector
- John J III BorerDirector
- Hermann LuebbertExecutive Officer, Director
- Erica F GatesExecutive Officer
- Offering amount
- $9.4M
- Amount sold
- $9.4M
- Sales commissions
- $660.1K
- Placement agents
- The Benchmark Company, LLC, Roth Capital Partners, LLC
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedDec 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedDec 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Erica F GatesExecutive Officer
- John J III BorerDirector
- Beth J HoffmanDirector
- Hermann LuebbertExecutive Officer, Director
- Loretta M WedgeDirector
- Erica L MonacoExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- Sales commissions
- $1.2M
- Placement agents
- Roth Capital Partners, LLC, The Benchmark Company, LLC
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$5.1Mvaluation at IPONov 2023 · $3.74/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 8
TipRanksFinancial analysis and stock research platform.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies working in the same space as Biofrontera.
Frequently asked questions
- What does Biofrontera do?
- Biofrontera develops treatments for actinic keratosis and other common skin conditions, aimed at improving outcomes for dermatology patients and providers. The company operates in the pharmaceutical and dermatology space.
- Who founded Biofrontera?
- Biofrontera was founded by Hermann Luebbert in 2015.
- How much funding has Biofrontera raised?
- Biofrontera has disclosed $58.4M raised across 7 rounds.
- Where is Biofrontera headquartered?
- Biofrontera is headquartered in Woburn, US.